US 12,233,084 B2
High purity RNA compositions and methods for preparation thereof
Stephen Hoge, Brookline, MA (US); William Issa, Dedham, MA (US); Edward J. Miracco, Arlington, MA (US); Jennifer Nelson, Brookline, MA (US); Amy E. Rabideau, Waltham, MA (US); and Gabor Butora, Martinsville, NJ (US)
Assigned to ModernaTX, Inc., Cambridge, MA (US)
Filed by ModernaTX, Inc., Cambridge, MA (US)
Filed on Nov. 10, 2021, as Appl. No. 17/523,060.
Application 17/523,060 is a continuation of application No. 16/333,330, granted, now 11,202,793, previously published as PCT/US2017/051674, filed on Sep. 14, 2017.
Claims priority of provisional application 62/394,711, filed on Sep. 14, 2016.
Prior Publication US 2022/0096522 A1, Mar. 31, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7105 (2006.01); A61P 31/04 (2006.01); A61P 31/12 (2006.01); A61P 33/00 (2006.01); A61P 35/00 (2006.01); C07K 14/505 (2006.01); C12N 15/10 (2006.01); C12P 19/34 (2006.01); G01N 33/68 (2006.01)
CPC A61K 31/7105 (2013.01) [A61P 31/04 (2018.01); A61P 31/12 (2018.01); A61P 33/00 (2018.01); A61P 35/00 (2018.01); C07K 14/505 (2013.01); C12N 15/10 (2013.01); C12P 19/34 (2013.01); G01N 33/6851 (2013.01)] 36 Claims
 
1. A method of producing a messenger ribonucleic acid (mRNA) that comprises an open reading frame encoding a vaccine antigen, the method comprising incubating a reaction mixture comprising a deoxyribonucleic acid (DNA), an RNA polymerase, buffer, adenosine triphosphate (ATP), cytidine triphosphate (CTP), 1-methylpseudouridine triphosphate (1-methylpseudo-UTP), and guanosine triphosphate (GTP), wherein the reaction mixture comprises the GTP in an amount greater than an amount of one or more of the ATP, CTP, and 1-methylpseudo-UTP, wherein the reaction mixture comprises two or more of the ATP, CTP, and 1-methylpseudo-UTP in equimolar amounts, thereby producing the mRNA.